Cantor Fitzgerald Has Positive View of LLY FY2025 Earnings

Key Points

• Cantor Fitzgerald has raised its FY2025 earnings estimate for Eli Lilly to $23.25 per share, maintaining an "Overweight" rating and a target price of $825.00.
• Eli Lilly reported earnings per share of $6.31 for the last quarter, surpassing analyst expectations of $5.59, with a significant 37.6% year-over-year revenue growth.
• The company has announced a quarterly dividend of $1.50 per share, representing an annualized yield of 0.9%.

Eli Lilly and Company (NYSE:LLY - Free Report) - Equities researchers at Cantor Fitzgerald upped their FY2025 earnings estimates for shares of Eli Lilly and Company in a research note issued to investors on Wednesday, August 13th. Cantor Fitzgerald analyst C. Gould now anticipates that the company will post earnings of $23.25 per share for the year, up from their previous estimate of $21.76. Cantor Fitzgerald currently has a "Overweight" rating and a $825.00 price objective on the stock. The consensus estimate for Eli Lilly and Company's current full-year earnings is $23.48 per share. Cantor Fitzgerald also issued estimates for Eli Lilly and Company's FY2026 earnings at $33.00 EPS.

Other equities research analysts have also issued reports about the stock. Guggenheim decreased their price objective on shares of Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a research report on Wednesday. Wells Fargo & Company reiterated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Leerink Partners reiterated a "market perform" rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Morgan Stanley restated an "overweight" rating and issued a $1,135.00 target price (up from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. Finally, Leerink Partnrs lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 7th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $964.88.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded up $17.08 on Friday, hitting $701.51. The company's stock had a trading volume of 8,211,278 shares, compared to its average volume of 6,346,453. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $972.53. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The firm has a fifty day moving average price of $764.55 and a 200-day moving average price of $794.63. The company has a market capitalization of $663.95 billion, a P/E ratio of 45.85, a price-to-earnings-growth ratio of 0.98 and a beta of 0.44.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the previous year, the firm earned $3.92 EPS. The business's revenue for the quarter was up 37.6% compared to the same quarter last year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is presently 39.22%.

Insider Buying and Selling at Eli Lilly and Company

In related news, CEO David A. Ricks acquired 1,632 shares of the business's stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the acquisition, the chief executive officer directly owned 546,601 shares in the company, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director J Erik Fyrwald acquired 1,565 shares of the business's stock in a transaction dated Tuesday, August 12th. The shares were bought at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the acquisition, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is currently owned by insiders.

Institutional Trading of Eli Lilly and Company

Institutional investors and hedge funds have recently bought and sold shares of the business. Knightsbridge Asset Management LLC increased its position in Eli Lilly and Company by 1.9% during the 4th quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company's stock worth $628,000 after purchasing an additional 15 shares in the last quarter. LS Investment Advisors LLC increased its position in Eli Lilly and Company by 1.7% during the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock worth $1,933,000 after purchasing an additional 40 shares in the last quarter. Prism Advisors Inc. acquired a new stake in Eli Lilly and Company during the 1st quarter worth approximately $207,000. CSM Advisors LLC increased its position in Eli Lilly and Company by 30.6% during the 4th quarter. CSM Advisors LLC now owns 1,045 shares of the company's stock worth $807,000 after purchasing an additional 245 shares in the last quarter. Finally, Hemington Wealth Management increased its position in Eli Lilly and Company by 14.4% during the 1st quarter. Hemington Wealth Management now owns 985 shares of the company's stock worth $813,000 after purchasing an additional 124 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.